McDermott Advises Myonex on Acquisition of Hubertus' Clinical Trial Business Unit - McDermott Will & Emery

McDermott Advises Myonex on Acquisition of Hubertus’ Clinical Trial Business Unit


Frankfurt/Main, Germany, October 7, 2022 – McDermott Will & Emery advised Myonex Inc, a leading global provider of clinical trial supply solutions, on its acquisition of the clinical trial supply and drug wholesale business from Hubertus Apotheke am Salzufer (Hubertus) in Berlin. The new company will operate under the name Myonex GmbH.

Myonex was founded 35 years ago and today globally offers a wide range of sourcing and supply, packaging, and labeling solutions, as well as distribution options to support clinical trials.

Hubertus had over 30 years of experience in the manufacture and distribution of clinical trial supplies and provided support for phase I to IV clinical trials.

The McDermott team advising Myonex was led by partner Deniz Tschammler and included counsel Jana Grieb as well as associates Lea Hachmeister and Katharina Hoffmeister.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts